Optinose Reports Additional Positive Results From ReOpen Trial Evaluating XHANCE

(RTTNews) - Optinose (OPTN) reported additional results from the ReOpen trial program evaluating XHANCE for treatment of patients with chronic sinusitis. The company said these pre-planned secondary analyses of data from the ReOpen2 trial and pooled data from both ReOpen1 and ReOpen2 found that patients using XHANCE in these trials experienced a spectrum of benefits on symptoms and quality of life, as well improvement in objective measures of disease, relative to patients receiving a placebo comparator.

The company noted that the safety profile and tolerability of XHANCE in these trials were consistent with its currently labelled safety profile.

For More Such Health News, visit rttnews.com.